Search - tctmd.com

Displaying 81 - 100 of 166

Sort: Relevancy | Date

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

Yael L. Maxwell

March 26, 2020

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

News Daily News

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

Yael L. Maxwell

December 26, 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

Advertisement

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Evinacumab Cuts LDL Cholesterol in Homozygous FH

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Statins Started in Kids With FH Provide Benefits in Adulthood

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Statin Discontinuation in the Elderly Linked to More CV Events

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content